SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer. 2014;120:572-579.
  • 2
    Blumenthal D, Tavenner M. The “meaningful use” regulation for electronic health records. N Engl J Med. 2010;363:501-504.
  • 3
    Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: Department of Health and Human Services, US Public Health Service; 2008.
  • 4
    Rabius V. Design and outcome of a comprehensive smoking cessation program for cancer patients. Paper presented at: Moon Shots: Connect for Global Networking, Global Academic Programs 2013 Conference; April 3, 2013; Houston, Texas.
  • 5
    Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients [serial online]. Cochrane Database Syst Rev. 2012;5:CD001837.
  • 6
    Gritz ER, Lam CY, Vidrine DJ, Fingeret MC. Tobacco dependence and its treatment. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2011:529-542.
  • 7
    Peppone LJ, Mustian KM, Morrow GR, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011;16:1784-1792.
  • 8
    Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol. 2012;19:1430-1438.
  • 9
    Ostroff JS, Jacobsen PB, Moadel AB, et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. Cancer. 1995;75:569-576.
  • 10
    Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012;52:321-336.
  • 11
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012;11:CD000146.
  • 12
    Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. Am J Psychiatry. 2013;170:860-867.
  • 13
    Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of 120 studies involving 177,390 individuals [serial online]. Tob Induc Dis. 2010;8:8.
  • 14
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031. DOI: 10.1002/14651858.CD000031.pub3. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000031.pub3/pdf. Accessed October 21, 2013.
  • 15
    Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-1056.
  • 16
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation [serial online]. Cochrane Database Syst Rev. 2008;3:CD006103.
  • 17
    Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008286. DOI: 10.1002/14651858.CD008286.pub2.
  • 18
    US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline). Rockville, MD: Department of Health and Human Services; 2008.
  • 19
    Cinciripini PM, Robinson JD, Karam-Hage M, et al. The effects of varenicline and bupropion-SR plus intensive counseling on prolonged abstinence from smoking, depression, negative affect and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-533.
  • 20
    Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51-61.
  • 21
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010;26:549-560.
  • 22
    Zimovetz EA, Wilson K, Samuel M, Beard SM. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Eval Clin Pract. 2011;17:288-297.
  • 23
    Anhang Price R, Stranges E, Elixhauser A. Cancer Hospitalizations for Adults, 2009. HCUP Reports. Healthcare Cost and Utilization Project, Statistical Brief no. 125. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb125.pdf. Accessed October 9, 2013.
  • 24
    Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253-1262.